Non-regulatory
announcement
Verici Dx
plc
("Verici Dx" or the
"Company")
Verici Dx
Launches an interactive
patient-focused educational tool, the Patient
Journey
Providing a detailed
overview of all stages of the kidney transplant
journey
Verici Dx (AIM: VRCI), a
developer of advanced clinical diagnostics for organ transplant, is
pleased to announce the introduction of its patient-focused education resource, for use by
patients, care
givers and transplant teams in the form of a new dedicated website showing the kidney transplant patient
journey (https://patientjourney.vericidx.com).
This online tool is designed to illustrate a generalised pathway
for patients as they consider their kidney healthcare and offer a
platform for patients to share their own experiences digitally
including video clips. It also includes video clips from
transplant team members to share their thoughts on what to
expect. This enhancement is part of
Verici Dx's ongoing commitment to supporting patients with
comprehensive and accessible information.
At Verici Dx, we are committed to
improving patient outcomes and believe that access to reliable,
detailed information is a cornerstone of effective
healthcare. This new tool provides a
detailed overview of all stages of the kidney transplant
journey-from the initial diagnosis and treatment of kidney disease, through
early-stage monitoring and on to long-term care after a kidney transplant. This resource is
designed to empower patients and caregivers with knowledge
and understanding, helping them navigate the
complexities of kidney disease
and transplantation with confidence.
The new section of the website is
intended to offer a valuable tool for those seeking guidance at
each step of their journey and we look forward to demonstrating
this to patients at the Transplant Games,
which will take place in Birmingham Alabama, from 5 - 10 July 2024.
We invite everyone
interested in learning more about the kidney transplant process to
join us there or visit our updated website at
https://patientjourney.vericidx.com.
Commenting on the update, Andrew Silverman, Director of
Scientific Communications, said:
"We are excited to launch this new
section of the website as it directly aligns with our mission to
enhance patient care and support. It ensures that
patients and
caregivers have access to the latest information and best practices
for kidney transplant care, and we are
confident that it will improve communication between all parties
involved in the journey."
Enquiries:
|
Verici Dx
|
www.vericidx.com
|
|
Sara Barrington, CEO
|
investors@vericidx.com
|
|
Julian Baines, Chairman
|
|
|
|
|
|
|
|
|
Singer Capital Markets (Nominated Adviser &
Broker)
|
Tel: +44 20 7496
3000
|
|
Aubrey Powell / Sam
Butcher
|
|
|
|
|
About Verici Dx plc www.vericidx.com
Verici Dx is a developer of a
complementary suite of leading-edge tests forming a kidney
transplant platform for personalised patient and organ response
risk to assist clinicians in medical management for improved
patient outcomes. The underlying technology is based upon
artificial intelligence assisted transcriptomic analysis to provide
RNA signatures focused upon the immune response and other
biological pathway signals critical for transplant prognosis of
risk of injury, rejection and graft failure from pre-transplant to
late stage. The Company also has a mission to accelerate the pace
of innovation by research using the fully characterised data from
the underlying technology, including through collaboration with
medical device, biopharmaceutical and data science
partners.
The foundational research was driven
by a deep understanding of cell-mediated immunity and is enabled by
access to expertly curated collaborative studies in highly
informative cohorts in kidney transplant.